In 2020, in response to the global COVID-19 pandemic, Acticor Biotech proposed using glenzocimab to treat acute respiratory distress syndrome (ARDS) in SARS-Cov-2 infected patients, in the context of a phase 2 clinical study (GARDEN NCT04659109).
The scientific rationale was to limit the contribution of platelets to uncontrolled pulmonary inflammation and prevent the secondary effects of a pro-thrombotic environment without inducing bleeding. The primary objective of the GARDEN study, involving 60 patients, is therefore to evaluate the efficacy of glenzocimab in preventing the clinical progression of disease when added to standard of care in COVID-19 patients presenting with ARDS. By June 2021, all patients had been enrolled in the study and the preliminary results are expected in the first quarter of 2022.
Acticor Biotech is also evaluating an extension to its clinical development program to include pulmonary embolism and myocardial infarction.
BREATH study is currently designed to compare the safety and efficacy of glenzocimab in the treatment of patients with sub-massive pulmonary embolism treated with increasing doses of alteplase.
LIBERATE study is a planned collaboration with University of Birmingham on a phase 2b clinical trial of glenzocimab in myocardial infarction.
In collaboration with SATT OUEST VALORISATION, Brest University Hospital, Université de Bretagne Occidentale, INSERM and EFS, Acticor Biotech is developing the early genomic profiling of stroke in order to design an emergency point-of-care device that will enable the rapid diagnosis of acute ischemic stroke and initiation of its treatment without additional imaging delays.